Drug Profile
Dubermatinib - Sumitomo Pharma America
Alternative Names: TP-0903Latest Information Update: 19 Jul 2023
Price :
$50
*
At a glance
- Originator Tolero Pharmaceuticals
- Developer Sumitomo Pharma America; Tolero Pharmaceuticals
- Class Aniline compounds; Antineoplastics; Piperazines; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Aurora kinase B inhibitors; Axl receptor tyrosine kinase inhibitors; Janus kinase-2 inhibitors; STAT6 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Chronic lymphocytic leukaemia
- Phase I Solid tumours
- Preclinical Breast cancer; Malignant melanoma
- No development reported Glioblastoma; Head and neck cancer; Lung cancer; Neuroblastoma
Most Recent Events
- 08 Jun 2023 Efficacy and adverse events data from a phase Ib/II Beat AML trial in Acute myeloid leukemia presented at the 28th Congress of the European Haematology Association (EHA-2023)
- 14 Apr 2023 Dubermatinib is still in preclinical phase trials for breast cancer in USA
- 14 Apr 2023 Pharmacodynamics data from preclinical studies in breast cancer presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)